Literature DB >> 14506211

Trends in antimalarial drug deployment in sub-Saharan Africa.

P B Bloland1, S P Kachur, H A Williams.   

Abstract

Antimalarial drug resistance is forcing newly developed pharmaceuticals into widespread use at an accelerating pace. To have the greatest public health impact, new pharmaceuticals will need to be deployed effectively in sub-Saharan Africa. Achieving effective antimalarial drug deployment over the short- to medium-term will require an appreciation of how drugs are currently used in Africa and the development of innovative approaches to optimize that use. Over the long-term, fundamental changes in the way that drugs are deployed will probably be required. There are many new strategies and initiatives that, to a greater or lesser degree, will influence how drugs are used. These influences may have a positive or negative effect on reducing malaria morbidity and mortality. The concept of analyzing and monitoring programmatic effectiveness allows for a more holistic understanding of these influences and allows for more unbiased, evidence-based decision making related to drug policy and deployment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14506211     DOI: 10.1242/jeb.00637

Source DB:  PubMed          Journal:  J Exp Biol        ISSN: 0022-0949            Impact factor:   3.312


  26 in total

Review 1.  Unit-dose packaged drugs for treating malaria.

Authors:  L Orton; G Barnish
Journal:  Cochrane Database Syst Rev       Date:  2005-04-18

2.  Novel Plasmodium vivax dhfr alleles from the Indonesian Archipelago and Papua New Guinea: association with pyrimethamine resistance determined by a Saccharomyces cerevisiae expression system.

Authors:  Michele D Hastings; Jason D Maguire; Michael J Bangs; Peter A Zimmerman; John C Reeder; J Kevin Baird; Carol Hopkins Sibley
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

3.  Chloroquine Resistant Plasmodium falciparum in Nigeria: Relationship between pfcrt and pfmdr1 Polymorphisms, In-Vitro Resistance and Treatment Outcome.

Authors:  O A Folarin; G O Gbotosho; A Sowunmi; O O Olorunsogo; A M J Oduola; T C Happi
Journal:  Open Trop Med J       Date:  2008

4.  Willingness to pay for rapid diagnostic tests for the diagnosis and treatment of malaria in southeast Nigeria: ex post and ex ante.

Authors:  Benjamin Sc Uzochukwu; Obinna E Onwujekwe; Nkoli P Uguru; Maduka D Ughasoro; Ogochukwu P Ezeoke
Journal:  Int J Equity Health       Date:  2010-01-15

5.  Factors determining anti-malarial drug use in a peri-urban population from malaria holoendemic region of western Kenya.

Authors:  Carren A Watsierah; Walter G Z O Jura; Henry Oyugi; Benard Abong'o; Collins Ouma
Journal:  Malar J       Date:  2010-10-26       Impact factor: 2.979

6.  Developing geostatistical space-time models to predict outpatient treatment burdens from incomplete national data.

Authors:  Peter W Gething; Abdisalan M Noor; Priscilla W Gikandi; Simon I Hay; Mark S Nixon; Robert W Snow; Peter M Atkinson
Journal:  Geogr Anal       Date:  2008-04

7.  Factors associated with non-adherence to Artemisinin-based combination therapy (ACT) to malaria in a rural population from holoendemic region of western Kenya.

Authors:  Elizabeth O Onyango; George Ayodo; Carren A Watsierah; Tom Were; Wilson Okumu; Samuel B Anyona; Evans Raballah; John M Okoth; Sussy Gumo; George O Orinda; Collins Ouma
Journal:  BMC Infect Dis       Date:  2012-06-24       Impact factor: 3.090

8.  Cost-effectiveness analysis of rapid diagnostic test, microscopy and syndromic approach in the diagnosis of malaria in Nigeria: implications for scaling-up deployment of ACT.

Authors:  Benjamin S C Uzochukwu; Eric N Obikeze; Obinna E Onwujekwe; Chima A Onoka; Ulla K Griffiths
Journal:  Malar J       Date:  2009-11-23       Impact factor: 2.979

9.  Malaria treatment perceptions, practices and influences on provider behaviour: comparing hospitals and non-hospitals in south-east Nigeria.

Authors:  Obinna Onwujekwe; Benjamin Uzochukwu; Nkem Dike; Nkoli Uguru; Emmanuel Nwobi; Elvis Shu
Journal:  Malar J       Date:  2009-10-28       Impact factor: 2.979

10.  A comparative, randomized clinical trial of artemisinin/naphtoquine twice daily one day versus artemether/lumefantrine six doses regimen in children and adults with uncomplicated falciparum malaria in Côte d'Ivoire.

Authors:  Offianan A Toure; Louis K Penali; Jean-Didier Yapi; Berenger A Ako; Walamtchin Toure; Kali Djerea; Genevieve O Gomez; Oyewole Makaila
Journal:  Malar J       Date:  2009-07-03       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.